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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
￿ Guidelines recommend that the therapeutic
goal of urate-lowering therapy (ULT) is to
achieve a urate concentration of 6m gd l
-1.
￿ High-dose allopurinol is associated with
reduced cardiovascular events and mortality
in heart failure patients.
WHAT THIS STUDY ADDS
￿ Less than 50% of patients taking allopurinol
reached target urate concentration.
￿ Higher doses of allopurinol were associated
with better control of urate and lower risks
of both cardiovascular events and mortality
in all patients on allopurinol treatment.
AIMS
To characterize patients with urate measurements by urate-lowering
therapy (ULT) use and to study the impact of allopurinol treatment on
cardiovascular and mortality outcomes.
METHODS
A cohort study using a record-linkage database.The study included
7135 patients aged 60 years with urate measurements between 2000
and 2002 followed up until 2007.A Cox regression model was used.The
association between urate levels,dispensed allopurinol and
cardiovascular hospitalization and mortality was determined.
RESULTS
Six thousand and forty-two patients were not taking ULT and 45.9% of
those (2774 of 6042) had urate concentrations 6m gd l -1.Among
1035 allopurinol users,44.7% (45.6% for men and 43.3% for women)
reached target urate concentration.There was no signiﬁcant increased
risk of cardiovascular events for allopurinol users when compared with
non-ULT users [adjusted hazard ratio (HR) 1.10,95% conﬁdence interval
(CI) 0.95–1.26] and the non-ULT group with urate >6m gd l -1 (adjusted
HR 1.07,95% CI 0.89–1.28).Within the allopurinol use cohort,
cardiovascular event rates were 74.0 (95% CI 61.9–86.1) per 1000
person years for the 100 mg group,69.7 (49.6–89.8) for the 200 mg
group and 47.6 (38.4–56.9) for the 300 mg group.Compared with
low-dose (100 mg) users,high-dose (300 mg) users had signiﬁcant
reductions in the risk of cardiovascular events (adjusted HR 0.69,95%
CI 0.50–0.94) and mortality (adjusted HR 0.75,95% CI 0.59–0.94).
CONCLUSIONS
Less than 50% of patients taking allopurinol reached target urate
concentration.Higher doses of allopurinol were associated with better
control of urate and lower risks of both cardiovascular events and
mortality.
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Allopurinol is a widely used urate-lowering therapy (ULT)
in patients with gout and hyperuricaemia.The therapeutic
aim is to lower serum urate levels and prevent the precipi-
tation of urate crystals. Clinical studies have shown that
maintaining serum uric acid levels 6.0 mg dl
-1 (or
0.36 mmol l
-1) results in a reduction in the incidence of
gout ﬂares, decreased numbers of urate crystals in aspi-
rated ﬂuid from joints and reductions in size and number
of tophi [1–3].
However, a signiﬁcant limitation of this therapy is that
the target urate level of 6.0 mg dl
-1 is achieved in less
than 50% of patients with gout receiving a standard dose
of 300 mg of allopurinol [4]. Recently it has been shown
that dose escalation may help to increase the success rate
of lowering urate to target levels [5].
Uric acid is an independent predictor of mortality
and cardiovascular events in both high-risk patients,
such as those with heart failure [6] and diabetes [7], and
the general population [8–10]. Allopurinol improves
endothelial function, defects in which are known to be
associated with progression of cardiovascular disease
[11]. We have previously found that high-dose
allopurinol is associated with reduced cardiovascular
events and mortality in heart failure patients [12]. How-
ever, it is not clear whether this ﬁnding extends to all
patients on allopurinol treatment. The present study is a
cohort study in all patients having urate concentration
measurements to determine the effect of allopurinol
on cardiovascular hospitalization and mortality
outcome.
Patients and methods
This study was carried out in the Tayside population of
Scotland, using the MEMO (MEdicines MOnitoring Unit)
record-linkagedatabase[13].TheMEMOdatabasecoversa
population that is geographically compact and serves
about 400 000 National Health Service in Scotland (NHSiS)
patients, 97% of whom are of white ethnic origin. The
NHSiS is tax funded,free at the point of consumption and
covers the entire population.In Tayside,there is almost no
healthcare delivered outwith the NHS and there is a low
rate of patient migration (less than 3% of patients aged 60
years or over left theTayside region overa5y e a rp e r i o do f
2004–2008). In brief, the database contains several data
setsincludingalldispensedcommunityprescriptions,hos-
pital discharge data,mortality data,biochemistry data and
otherdatathatarelinkedbyauniquepatientidentiﬁer,the
community health index number.The data have been vali-
dated and made anonymous for the purposes of research
as approved by the government-appointed guardians of
patient conﬁdentiality (the Tayside Caldecott Guardians).
The project was also approved by the Tayside Research
Ethics Committee.
Study design
This was a cohort study using a UK record-linkage
database.
Study subjects
The study subjects included all patients from the hospitals
and communities who had urate concentration measure-
ments between January 2000 and December 2002 and
were aged 60 years old or over (i.e. the entire cohort of
those who had urate measured within the region). They
were either resident in Tayside throughout the study
period of January 2000 to December 2007 (i.e. a ﬁxed
cohort with complete follow-up for each patient) or died
during the study period.
If patients had more than one urate measurement,the
last measurement was used for the study. They were
divided into three groups according to whether they were
onULTduringthesameperiod:(i)allopurinolusegroup;(ii)
other ULT use group; and (iii) non-ULT use group. Within
the allopurinol use group, subjects were further divided
into three groups according to allopurinol daily dose (i.e.
100,200 and 300 mg).There were only two patients who
had a daily dose of 150 mg and they were categorized into
the 200 mg group.
Patients with a diagnosis of cancer or hospitalization
malignancy (International Classiﬁcation of Disease (ICD)
codes of C00-C97 and D00-D09) before the time of entry
into the study were excluded from the analysis.
Deﬁnition of APTC end-point
The Antiplatelet Trialists’ Collaboration (APTC) combined
end-point of nonfatal myocardial infarction, nonfatal
stroke and cardiovascular mortality was used in this study
[14]. Outcomes were ascertained from the hospital dis-
charge diagnosis data,Scottish Mortality Record-1 (SMR1)
coded by primary International Classiﬁcation of Diseases
(ICD)-9 codes and ICD-10 code and from death certiﬁca-
tion from the General Register Ofﬁce in Scotland.
Outcome variables
The outcomes of the study were the APTC combined end-
point and all-cause mortality during the follow-up period
until December 2007. The minimal follow-up for each
subject was 5 years.
Covariates
Covariates included age, sex and Carstair’s deprivation
code (derived from patients’ postcode and 2001 census
data comprising social class, overcrowding, male unem-
ployment and car ownership),prior hospitalization for car-
diovasculardisease,goutorhyperuricaemia,hypertension,
renal disease and diabetes mellitus, cardiovascular drugs
including aspirin, anticoagulants, angiotensin-converting
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b-blockers, cardiac glycosides, thiazide diuretics, other
diuretics, nitrates and calcium-channel blockers, diabetes
drugs,nonsteroidal anti-inﬂammatory drugs (NSAIDs),ste-
roids or colchicine at baseline or any time during the
follow-up.
Statistical analysis
Data were summarized as means (standard deviations) for
continuous variables and numbers of subjects (percent-
ages) for categorical variables. Data distributions and Cox
model assumption were checked before any statistical
tests were carried out. Chi-square and t-tests were per-
formed to determine signiﬁcant differences.The Cox pro-
portional hazard model was used to compare risks of
cardiovascular event or mortality between the allopurinol
daily dosage groups.To minimize confounding by indica-
tion, where patients with more severe illness are more
likely to be treated with allopurinol, we calculated a pro-
pensity index for each subject, i.e. the likelihood that a
patient would be treated by allopurinol based on known
baseline characteristics. A propensity score matched
cohort analysis was carried out for the high-dose allopu-
rinolgroupvs.thelow-doseallopurinolgroup.Allstatistical
analyses were carried out using SAS (Statistical Analysis
System) software version 9.1 (SAS Institute,Cary,NC,USA).
Prespeciﬁed sensitivity analysis
A number of sensitivity analyses were performed subse-
quent to the primary analysis of the data. Firstly, we
matchedforbaselineuratelevelfortheincidenthigh-dose
allopurinol users and non-ULT users to see whether high-
dose allopurinol reduced events/mortality over non-ULT
takers (sensitivity 1).Secondly,we used the ﬁrst urate mea-
surement instead of the last measurement for the analysis
(sensitivity 2).Thirdly, we re-ran the analysis by excluding
patients with renal disease (sensitivity 3). Fourthly, we
repeated the analysis by removing patients with previous
cardiovascular disease (sensitivity 4).
Results
There were 7135 study subjects. Of these, 1093 (15.3%)
were taking ULT treatment.Among the ULT users,94.7% (n
=1035)weretakingallopurinoltreatmentandonly5.3%(n
= 58) were on other ULT treatments (colchicine,sulﬁnpyra-
zone and probenecid).Table 1 shows the characteristics of
patients who were on allopurinol and those who were not
on any ULT treatment. There were no signiﬁcant differ-
ences in age, urate concentration, social deprivation and
previous hospitalizations for diabetes mellitus or hyper-
tension between the allopurinol and non-ULT groups.
However, patients in the allopurinol group were more
likely to be male,had more co-morbidities and more con-
current drug use than patients in the non-ULT group (P <
0.05; Table 1). Table 2 shows the patient characteristics of
the different allopurinol dose groups.Patients in the high
daily dose group (432 patients were prescribed 300 mg or
more but of these,only 12 patients were prescribed more
than 300 mg allopurinol per day) were signiﬁcantly
younger,more likely to be male,had less renal disease and
diabetes,lessuseofanticoagulantsanddiureticsandmore
use of NSAIDs than the lower dose groups.
Urate concentration target and allopurinol
treatment
The proportion of patients reaching target urate concen-
trations (deﬁned as 6m gd l
-1) in the allopurinol use
group was 44.7% overall [45.6% of men (295 of 647) and
43.3% of women (168 of 388); P < 0.01]. Looking at the
effects of daily dose of allopurinol, the proportions of
patients with urate concentrations attaining target levels
for men and women were 24.2 and 24.4% for 100 mg,40.6
and 56.9% for 200 mg and 64.7 and 66.7% for 300 mg or
over,respectively (Table 3).Women tended to be on lower
doses of allopurinol compared with men [51.8 (201 on
100 mg) vs. 38.3% (248 on 100 mg), P < 0.01;Table 3].The
median age was 73 years old (interquartile range 67–79)
for the 100 mg group, 73 years old (interquartile range
66–79) for the 200 mg group and 71 years old (interquar-
tile range 65–77) for the 300 mg or over group.
Cardiovascular event rates and all-cause
mortality
Comparison between the allopurinol cohort and non-ULT
cohort There were 1145 cardiovascular events and 1943
deaths in the non-ULT use group (with 732 cardiovascular
events and 1218 deaths in those with a urate level
>6m gd l
-1) and 273 cardiovascular events and 475 deaths
intheallopurinolgroupduringamedianfollow-uptimeof
5.6years.Thecardiovasculareventrateswere38.5per1000
person years [95% conﬁdence interval (CI) 36.3–40.7] for
thenon-ULTusegroup,48.5per1000personyears(95%CI
45.1–51.9)forthenon-ULTgroupwithurate>6m gd l
-1and
61.4 per 1000 person years (95% CI 54.3–68.4) for the
allopurinol use group.There was no signiﬁcant increased
risk of cardiovascular events for allopurinol users when
compared with the non-ULT users [adjusted hazard ratio
(HR) 1.10, 95% CI 0.95–1.26] and the non-ULT group with
urate >6m gd l
-1 (adjusted HR 1.07, 95% CI 0.89–1.28). A
further propensity score matched analysis of allopurinol
users vs. non-ULT users showed that the adjusted HR was
0.88,95%CI0.73–1.05.Withinthenon-ULTusegroup,there
was a strong relationship between urate concentration
and cardiovascular outcome (Figure 1). However, in the
allopurinol use group, the risk of adverse outcome
decreased with increased ULT dose (Figure 2), and the
effect of allopurinol did not depend on the urate concen-
tration.Therewasnoclearrelationshipbetweenuratecon-
centration and cardiovascular outcome in Figure 2 except
withthehigh-dosegroup,andthisisprobablyduetosmall
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Comparison within the allopurinol cohort In the allopu-
rinol use group, cardiovascular event rates were 61.3 per
1000personyears(95%CI54.3–68.4),74.0per1000person
years (95% CI 61.9–86.1) for the 100 mg daily group, 69.7
per 1000 person years (95% CI 49.6–89.8) for the 200 mg
group and 47.6 per 1000 person years (95% CI 38.4–56.9)
for the 300 mg and over group. Only one cardiovascular
event occurred in the 12 patients who took more than
300 mgallopurinolperday.Table 4showsthehazardratios
of cardiovascular disease and all-cause mortality in the dif-
ferent dose groups. The 300 mg and over group had sig-
niﬁcantly lower risk for both cardiovascular events and all-
cause mortality than the 100 mg group (adjusted HR 0.69,
95% CI 0.50–0.94 and adjusted HR 0.75,95% CI 0.59–0.94,
respectively).TheadjustedHRofcardiovasculareventswas
0.63, 95% CI 0.44–0.91, for a propensity score matched
analysis of high-dose vs.low-dose allopurinol therapy.The
death rates per 1000 person years in the allopurinol use
group were 100.7 (95% CI 92.2–109.3) overall, 120.3 (95%
CI 105.8–134.9) for the 100 mg group,108.6 (95% CI 84.9–
132.3) for the 200 mg group and 73.2 (95% CI 62.2–84.2)
for the 300 mg and over group.
Results of sensitivity analyses The risks of cardiovascular
and mortality outcomes in the allopurinol group changed
littlewhencomparedwiththenon-ULTgroup.Theresultsof
sensitivity analysis 1 (i.e.incident high-dose group vs. non-
ULTgroup)showedthattheadjustedHRsforcardiovascular
eventsandall-causemortalitywere0.54(95%CI0.32–0.92)
and 0.96 (95% CI 0.55–1.68), respectively. Compared with
the100 mggroup,theHRswere0.73(95%CI0.54–0.99)and
0.76(95%CI0.61–0.96)forsensitivityanalysis2,0.68(95%CI
0.49–0.95)and0.76(95%CI0.59–0.96)forsensitivityanaly-
sis3and0.62(95%CI0.44–0.86)and0.75(95%CI0.58–0.97)
for sensitivity analysis 4,respectively.
Table 1
Characteristics of patients by allopurinol use status
Allopurinol group n (%) Non-ULT group n (%) P-value
Number 1035 6042 –
Gender
Men 647 (62.5) 2843 (47.1) <0.01
Women 388 (37.5) 3199 (52.9) –
Age (mean, SD) 72.6 (7.8) 72.4 (7.1) 0.43
Social deprivation
1 64 (6.2) 393 (6.6) 0.60
2 192 (18.6) 1175 (19.7) –
3 268 (26.0) 1658 (27.8) –
4 102 (9.9) 563 (9.4) –
5 116 (11.2) 580 (9.7) –
6 and 7 290 (28.1) 1101 (26.8) –
Urate concentration (mg dl-1)
6 463 (44.7) 2774 (45.9) 0.65
6.01–7 200 (19.3) 1162 (19.2) –
7.01–8 140 (13.5) 871 (14.4) –
8.01–9 104 (10.1) 544 (9.0) –
>9 128 (12.4) 691 (11.4) –
Previous hospitalization
Diabetes mellitus 6 (0.6) 17 (0.3) 0.12
Gout or hyperuricaemia 19 (1.8) 26 (0.4) <0.01
Renal disease 77 (7.4) 209 (3.5) <0.01
Cardiovascular disease 100 (9.7) 437 (7.2) <0.01
Hypertension 8 (0.8) 38 (0.6) 0.59
Drugs in concurrent use
Aspirin 506 (48.9) 2312 (38.3) <0.01
Anticoagulants 127 (12.3) 360 (6.0) <0.01
Angiotensin-converting enzyme inhibitors 373 (36.0) 1556 (25.8) <0.01
b-Blockers 274 (26.5) 1188 (19.7) <0.01
Cardiac glycosides 131 (12.7) 329 (5.5) <0.01
Calcium-channel blockers 314 (30.3) 1553 (25.7) <0.01
Thiazides 106 (10.2) 1068 (17.7) <0.01
Other diuretics 513 (49.6) 1503 (24.9) <0.01
Nitrates 273 (26.4) 936 (15.5) <0.01
Statins 371 (35.9) 1602 (26.5) <0.01
Nonsteroidal anti-inﬂammatory drugs 328 (31.7) 1490 (24.7) <0.01
Colchicine 66 (6.0) 1 (0.2) <0.01
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Characteristics of patients by daily dose in the allopurinol users
100 mg n (%) 200 mg n (%) 300 mg n (%) P-value
Number 449 154 432 –
Gender
Men 248 (55.2) 96 (62.3) 303 (70.1) <0.01
Women 201 (44.8) 58 (37.7) 129 (29.9) –
Age (mean, SD) 73.2 (7.8) 72.9 (7.8) 71.8 (7.8) 0.02
Social deprivation
1 31 (6.9) 8 (5.2) 25 (5.8) 0.56
2 88 (19.6) 35 (22.7) 69 (16.1) –
3 105 (23.4) 39 (25.3) 124 (28.4) –
4 49 (10.9) 15 (9.7) 38 (8.8) –
5 54 (12.1) 18 (11.7) 44 (10.2) –
6 and 7 121 (27.0) 39 (25.3) 130 (30.2) –
Urate concentration (mg dl-1)
6 109 (24.3) 72 (46.7) 282 (65.3) <0.01
6.01–7 104 (23.2) 42 (27.3) 54 (12.5) –
7.01–8 91 (20.3) 13 (8.4) 36 (8.3) –
8.01–9 66 (14.7) 18 (11.7) 20 (4.6) –
>9 79 (17.6) 9 (5.8) 40 (9.3) –
Previous hospitalization
Diabetes mellitus 2 (0.5) 3 (2.0) 1 (0.2) 0.05
Gout or hyperuricaemia 10 (2.2) 2 (1.3) 7 (1.6) 0.69
Renal disease 54 (12.0) 15 (9.7) 8 (1.9) <0.01
Cardiovascular disease 46 (10.2) 13 (8.4) 41 (9.5) 0.80
Hypertension 5 (1.1) 1 (0.7) 2 (0.5) 0.53
Drugs in concurrent use
Aspirin 208 (46.3) 83 (53.9) 215 (49.8) 0.24
Anticoagulants 69 (15.4) 18 (11.7) 40 (9.3) 0.02
Angiotensin-converting enzyme inhibitors 160 (35.6) 55 (35.7) 158 (36.6) 0.95
b-Blockers 124 (27.6) 42 (27.3) 108 (25.0) 0.66
Cardiac glycosides 63 (14.0) 15 (9.7) 53 (12.3) 0.37
Calcium-channel blockers 147 (32.7) 50 (32.5) 117 (27.1) 0.16
Thiazides 48 (10.7) 15 (9.7) 43 (10.0) 0.91
Other diuretics 257 (57.2) 76 (49.4) 180 (41.7) <0.01
Nitrates 125 (27.8) 37 (24.0) 111 (25.7) 0.60
Statins 153 (34.1) 65 (42.2) 153 (35.4) 0.19
Nonsteroidal anti-inﬂammatory drugs 144 (32.1) 26 (16.9) 158 (36.6) <0.01
Colchicine 17 (3.8) 6 (3.9) 8 (1.9) 0.19
Table 3
Distribution of urate concentration (mg dl
-1) in patients aged 60 years and over by allopurinol daily dose
Daily dose (mg)
Urate concentration (mg dl-1)
n (%)
Percentage of
patients reaching
target (6m gd l -1)
6 6.01–7 7.01–8 8.01–9 >9
Men (n = 647)
100 60 (20.34) 60 (43.48) 50 (60.24) 41 (63.08) 37 (56.06) 24.19
200 39 (13.22) 33 (23.91) 9 (10.84) 13 (20.00) 2 (3.03) 40.63
300 196 (66.44) 45 (32.60) 24 (28.91) 11 (16.92) 27 (40.91) 64.69
Total 295 (100.00) 138 (100.00) 83 (100.00) 65 (100.00) 66 (100.00) 45.60
Average dose 253 mg 191 mg 172 mg 153 mg 184 mg
Women (n = 388)
100 49 (29.17) 44 (70.97) 41 (71.93) 25 (64.10) 42 (67.74) 24.38
200 33 (19.64) 9 (14.52) 4 (7.02) 5 (12.82) 7 (11.29) 56.90
300 860 (51.19) 9 (14.52) 12 (21.05) 9 (23.08) 13 (20.97) 66.67
Total 168 (100.00) 62 (100.00) 57 (100.00) 39 (100.00) 62 (100.00) 43.30
Average dose 226 mg 144 mg 149 mg 158 mg 152 mg
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In this study, we found that less than half of patients
reached target urate concentration,and high-dose allopu-
rinol was associated with reduced cardiovascular events
andall-causemortality.Theresultssuggestthatthebeneﬁt
ofhigh-doseallopurinolobservedinthehigh-riskpatients,
suchasthosewithdiabetesorheartfailure[6,12,15],could
be extended to all patients who taking allopurinol. We
have done a number of post hoc sensitivity analyses for
the study to make sure our results were consistent.All the
results were similar to the primary results except that the
risk reduction of mortality for the incident high-dose
group became statistically nonsigniﬁcant when compared
with the non-ULT group in sensitivity 1.
Previous evidence has suggested that high-dose
allopurinol may be associated with reduced risk of
mortality and cardiovascular events through its
patho-physiological pathway [16] by the following two
mechanisms: higher doses of allopurinol may have an
increased ability to improve endothelial function; and
higher doses may also improve cardiac structure [17].
These two mechanisms are noteworthy because both
endothelialfunctionandcardiacfunctionareindependent
predictors of mortality [7,18,19].Other mechanisms could
contribute, such as allopurinol reducing myocardial
oxygen consumption for a particular stroke volume, and
this has been conﬁrmed in a randomized clinical trial in
patients with chronic stable angina [20].Notably, a recent
crossover trial in 30 adolescents with newly diagnosed,
never-treated stage 1 essential hypertension and serum
uric acid levels 6m gd l
-1 showed that allopurinol
reduced mean 24 h ambulatory systolic and diastolic
blood pressures [21]. This implies that treatment with
allopurinol may reduce blood pressure, which could
potentially reduce the risk of cardiovascular disease.More
recently,Luk et al.reported a signiﬁcant survival beneﬁt of
allopurinoltreatmentinhyperuricaemicpatients(adjusted
HR 0.78, 95% CI 0.67–0.91) [22]. We also observed this
beneﬁt in our high-dose group when compared with non-
ULT patients (sensitivity 1).
The EULAR (European League Against Rheumatism)
guideline has recommended that the therapeutic goal of
ULTistoachieveaurateconcentration6m gd l
-1[23].The
allopurinol dose should be increased progressively until a
target urate concentration or maximal tolerated doses are
achieved [24].Our study showed that less than half of the
patients achieved this goal. However, there was a strong
dose–response relationship between allopurinol dose and
urateconcentration,withabouttwo-thirdsofpatientswho
were on 300 mg daily dose achieving this goal.This high-
lights that dose adjustment should be considered in order
to achieve the maximal beneﬁt of the therapy in routine
clinical practice. Our study result was consistent with the
ﬁnding that the proportion of gout patients achieving
their target urate concentration level (6m gd l
-1)w a s
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creatinine clearance) compared with those taking lower
than recommended doses (38 vs. 19%; P < 0.01) [25]. A
recent clinical trial in stroke patients also showed that
there was a dose–response relationship for reduction of
uric acid level by allopurinol at 6 weeks (reductions in uric
acid were 0.14 mmol l
-1 for the 300 mg group and
0.02 mmol l
-1 for the 100 mg group) [26].
Thestrengthsofthepresentstudyareasfollows.(i)The
study was a population-based cohort design with com-
plete follow-up over the study period.Unlike clinical trials,
which focus on highly selected patients,our study method
allowsfora‘real-world’populationtobestudied,represent-
ing all socio-economic groups and within a universal
healthcarecoveragescheme[27].(ii)Acompletebiochem-
istry database was available for this population.(iii) MEMO
only collects dispensed prescribing data and so primary
noncompliancewaseliminatedasasourceoferror[28].(iv)
Our study also had details of concomitant drug treatment.
The limitations of this study are as follows. (i) MEMO
does not have information on certain risk factors, such as
lifestyle, i.e. body mass index, smoking, alcohol and exer-
cise. These limitations are not unique to MEMO’s record-
linkage database; other databases also do not have
routinely collected information on lifestyle or drug indica-
tion.However,weusedasocio-economicdeprivationscore
as a surrogate marker for this,as data from Scotland have
shown that there is a signiﬁcant correlation between body
mass index, smoking and social deprivation [29]. (ii) We
assumed that if a prescription was ﬁlled then patients
wouldadheretotreatment,butwehadnowayofknowing
whetherornotsubjectstookthemedication.(iii)Ourstudy
also did not account for whether subsequent to the urate
measurement used in the analysis, patients might have
had a change in their allopurinol dosage.(iv) Although we
have used multivariate analyses, observational studies
cannot exclude residual confounding factors. (v) We did
not obtain information on adverse secondary effects of
high-dose allopurinol use in this study. Further investiga-
tion is needed to clarify this issue.
In conclusion, more than half of the patients taking
allopurinol did not reach the recommended target urate
levels. High-dose allopurinol use was associated with a
lower risk of cardiovascular events and all-cause mortality
than low-dose allopurinol use, suggesting that higher
doses of allopurinol may be of beneﬁt by reducing cardio-
vascular disease or death.
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